Germany · Delayed Price · Currency is EUR bioXXmed AG Statistics
Total Valuation
bioXXmed AG has a market cap or net worth of EUR 193,025. The enterprise value is -60,836.
| Market Cap | 193,025 |
| Enterprise Value | -60,836 |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
bioXXmed AG has 1.36 million shares outstanding. The number of shares has increased by 164.59% in one year.
| Current Share Class | 1.36M |
| Shares Outstanding | 1.36M |
| Shares Change (YoY) | +164.59% |
| Shares Change (QoQ) | +329.18% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 55.26 |
| PB Ratio | 0.61 |
| P/TBV Ratio | 0.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.06 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.04
| Current Ratio | 4.04 |
| Quick Ratio | 3.15 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -252.84% and return on invested capital (ROIC) is -136.89%.
| Return on Equity (ROE) | -252.84% |
| Return on Assets (ROA) | -93.01% |
| Return on Invested Capital (ROIC) | -136.89% |
| Return on Capital Employed (ROCE) | -214.34% |
| Revenue Per Employee | 3,493 |
| Profits Per Employee | -996,907 |
| Employee Count | 1 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.62% in the last 52 weeks. The beta is 1.03, so bioXXmed AG's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | -94.62% |
| 50-Day Moving Average | 0.26 |
| 200-Day Moving Average | 0.69 |
| Relative Strength Index (RSI) | 44.36 |
| Average Volume (20 Days) | 326 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, bioXXmed AG had revenue of EUR 3,493 and -996,907 in losses. Loss per share was -0.73.
| Revenue | 3,493 |
| Gross Profit | 3,493 |
| Operating Income | -871,534 |
| Pretax Income | -996,907 |
| Net Income | -996,907 |
| EBITDA | -786,534 |
| EBIT | -871,534 |
| Loss Per Share | -0.73 |
Balance Sheet
The company has 253,855 in cash and n/a in debt, giving a net cash position of 253,855 or 0.19 per share.
| Cash & Cash Equivalents | 253,855 |
| Total Debt | n/a |
| Net Cash | 253,855 |
| Net Cash Per Share | 0.19 |
| Equity (Book Value) | 318,617 |
| Book Value Per Share | 0.23 |
| Working Capital | 246,071 |
Cash Flow
| Operating Cash Flow | -916,000 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -24,950.87% |
| Pretax Margin | -28,540.14% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
bioXXmed AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -164.59% |
| Shareholder Yield | -164.59% |
| Earnings Yield | -516.47% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 12, 2024. It was a reverse split with a ratio of 0.1.
| Last Split Date | Aug 12, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
bioXXmed AG has an Altman Z-Score of -124.78 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -124.78 |
| Piotroski F-Score | 2 |